<DOC>
	<DOC>NCT01413048</DOC>
	<brief_summary>The purpose of this study is to evaluate the antihypertensive effect of AGSCT101 tablet in patient with stage 1 to 2 essential hypertension.</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension</brief_title>
	<detailed_description>This study is 2,8 weeks, multi-center, randomized, double-blind, active clinical trial to evaluate the efficacy and safety of AGSCT101 versus Carvedilol in patient with stage 1 to 2 essential hypertension.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Male or female outpatients â‰¥ 19 years of age Mild to moderate essential hypertension: sDBP 90 ~ 109, sSBP 140 ~ 179 Subjects who agree to participate in this sudy and give written informed consent Subjects considered to understand the study, be cooperative, and able to be followedup until the end of the study The sitting DBP is more than 110mmHg or the sitting SBP over 180mmHg Patients with postural hypotension Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological or hepatic(AST, ALT more 3 times more than upper limit of normal)disease Female of childbearing potential who does not undergo hysterectomy or is not postmenopausal Patients judged to have a history of alcohol or drug abuse by the investigator Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months Patients with uncontrolled diabetes mellitus Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Essential Hypertension</keyword>
	<keyword>Hypertension</keyword>
</DOC>